Low desire, changes in arousal, or difficulty with sexual function can affect confidence, intimacy, and relationships. Because these concerns may involve hormones, medications, stress, menopause, physical health, or relationship factors, identifying the underlying cause is an important first step.
Depending on the cause, some peptides for sexual wellness may be considered for pathways related to sexual desire or reproductive hormone signaling. Their roles and supporting evidence differ between women and men.
Sikora Integrative Medicine provides personalized peptide therapy based on each patient’s symptoms, health needs, and sexual wellness concerns. Care may address desire, arousal, or reproductive health within a medically supervised plan.
Different peptides relate to specific aspects of sexual and reproductive health:
Benefits vary by compound, diagnosis, and patient. Peptides for libido do not address every cause of sexual dysfunction, and some applications remain investigational.
The peptide list includes options connected with sexual and reproductive wellness. These peptides may relate to desire, arousal, or reproductive hormone signaling, but their uses and supporting evidence differ.
Bremelanotide for sexual wellness is associated with sexual desire and response. The FDA-approved injection, Vyleesi, is indicated for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD.
Vyleesi is not approved for postmenopausal women, men, erectile dysfunction, or performance enhancement. Prescribing Vyleesi outside its approved indication would be off-label. Its approval does not apply to compounded PT-141 preparations.
Kisspeptin-10 regulates the reproductive hormone axis and can stimulate luteinizing hormone and follicle-stimulating hormone. These effects influence ovarian and testicular function, giving it a reproductive and hormonal role rather than an established use for low libido or erectile dysfunction.
Peptide therapy for sexual health may be considered when sexual wellness concerns are persistent and have been medically evaluated. It may be relevant for adults who:
Suitability depends on the symptoms, health history, current treatments, and specific peptide. The purpose is to address an identified concern within a broader sexual wellness plan, not to provide general performance enhancement.
Sexual concerns can have different causes and treatment needs. Peptide therapy should be matched to the symptoms, diagnosis, and individual health factors.
When evaluating peptides for women’s sexual health, relevant factors may include:
An evaluation for peptides for men’s sexual health may need to distinguish between:
Some sexual health changes need diagnosis before peptide therapy is considered. Further evaluation is important with:
Erectile difficulties can have vascular, neurological, hormonal, psychological, or medication-related causes. Peptide therapy should not delay appropriate cardiovascular, gynecologic, urologic, or mental health care.
Safety considerations for peptides for sexual wellness vary by option, formulation, and individual health factors.
Blood pressure and cardiovascular health should be reviewed before use. Vyleesi is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
Kisspeptin-10 affects reproductive hormone signaling, making individual review important when fertility, pregnancy, medications, or hormone-related conditions are relevant. It is not FDA-approved for sexual dysfunction. Human safety data are limited, and Vyleesi’s prescribing information does not establish its safety. The FDA has identified potential compounding safety concerns for Kisspeptin-10.
Medical review and monitoring should reflect the peptide, formulation, and patient.
Sexual concerns may involve hormone levels, local tissue health, circulation, or several factors at once. Other services may offer a different or complementary approach:
The appropriate path depends on whether the concern involves desire, erectile response, discomfort, reproductive signaling, hormone balance, or local tissue health.
Related reading: Peptides for anti-aging and longevity examines broader healthy-aging research and its limits.
PT-141 is a peptide-based option that activates melanocortin receptors in the nervous system. Sildenafil and similar medications work primarily through blood flow, so their indications, risks, and approved patient populations differ.
No. Some sexual wellness peptides act on desire-related pathways, while others influence reproductive hormone signaling. Hormone therapy directly supplements or modifies hormone levels and requires a separate evaluation.
FDA-approved bremelanotide is injected under the skin as needed at least 45 minutes before anticipated sexual activity. Prescribing information limits it to a single dose within 24 hours and recommends no more than 8 doses per month.
Bremelanotide has been studied with sildenafil in men, but combining treatments is not appropriate for everyone. Blood pressure, cardiovascular health, medications, and the cause of erectile difficulties should be reviewed first.
Coverage depends on the peptide, diagnosis, formulation, and insurance plan. Coverage for FDA-approved Vyleesi may differ from compounded or off-label peptide therapy, so benefits and out-of-pocket costs should be confirmed before treatment.
Sexual desire, arousal, erectile function, and reproductive hormones require different forms of evaluation. Sikora Integrative Medicine can help identify the factors affecting your sexual health and determine whether PT-141, hormone care, peptide therapy, or another wellness option fits your needs.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, or cure any condition. Evidence and regulatory status vary by compound, formulation, use, and patient population. Consult a qualified healthcare professional for personalized recommendations. Services are available to Florida residents only.
© 2026 Sikora Integrative Medicine. All Rights Reserved.
© 2026 Sikora Integrative Medicine.
All Rights Reserved.